B. Riley Initiates Coverage on Inogen (NASDAQ:INGN)

B. Riley started coverage on shares of Inogen (NASDAQ:INGN - Free Report) in a report released on Monday, MarketBeat reports. The brokerage issued a buy rating and a $14.00 price objective on the medical technology company's stock. B. Riley also issued estimates for Inogen's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.72) EPS.

Other analysts have also issued reports about the stock. Stifel Nicolaus dropped their price target on shares of Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research report on Thursday, May 8th. Wall Street Zen lowered shares of Inogen from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price target on the stock in a research report on Thursday, May 22nd.

Inogen Stock Up 1.9%

Shares of INGN stock traded up $0.12 during trading on Monday, reaching $6.60. The company's stock had a trading volume of 140,538 shares, compared to its average volume of 241,598. The business has a fifty day moving average price of $6.65 and a 200-day moving average price of $8.29. Inogen has a one year low of $5.70 and a one year high of $13.33. The company has a market cap of $177.47 million, a price-to-earnings ratio of -5.74 and a beta of 1.64.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.27. Inogen had a negative net margin of 8.08% and a negative return on equity of 14.76%. The firm had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. Research analysts anticipate that Inogen will post -1.73 EPS for the current year.

Hedge Funds Weigh In On Inogen

Several large investors have recently modified their holdings of INGN. Ieq Capital LLC bought a new position in shares of Inogen in the fourth quarter valued at about $94,000. Bank of New York Mellon Corp raised its position in shares of Inogen by 23.5% in the fourth quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company's stock valued at $1,160,000 after purchasing an additional 24,082 shares during the period. AlphaQuest LLC bought a new position in shares of Inogen in the fourth quarter valued at about $43,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Inogen by 42.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 248,822 shares of the medical technology company's stock valued at $2,282,000 after purchasing an additional 74,197 shares during the period. Finally, Monaco Asset Management SAM raised its position in shares of Inogen by 104.0% in the fourth quarter. Monaco Asset Management SAM now owns 76,500 shares of the medical technology company's stock valued at $702,000 after purchasing an additional 39,000 shares during the period. 89.94% of the stock is owned by institutional investors.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.